Details for Patent: 7,982,043

Which drugs does patent 7,982,043 protect, and when does it expire?

Patent 7,982,043 protects NERLYNX and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 7,982,043

Title:	Protein tyrosine kinase enzyme inhibitors
Abstract:	This invention provides compounds of formula 1, having the structure ##STR00001## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are described within the specification.
Inventor(s):	Wissner; Allan (Ardsley, NY), Rabindran; Sridhar Krishna (Chestnut Ridge, NY), Tsou; Hwei-Ru (New City, NY)
Assignee:	Wyeth LLC (Madison, NJ)
Application Number:	12/136,357
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 7,982,043

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes						EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes						USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes						EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY

International Family Members for US Patent 7,982,043

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2005028443